腦脊髓液管理市場規模、佔有率和趨勢分析 |全球| 2026–2032 | 包括腦脊髓液分流器和體外腦脊髓液引流系統

2025年全球腦脊髓液（CSF）管理市場規模約3.27億美元。預計該市場將以2.8%的複合年成長率成長，到2032年達到約3.97億美元。

• 本報告重點在於兩大類醫療器材：腦脊髓液分流器和腦脊髓液外引流系統。該報告對銷售量、手術量、平均售價、市場規模、成長率和企業市場占有率進行了定量分析，包括截至2022年的歷史數據和截至2032年的預測數據。

新型分流技術和顱內壓（ICP）監測技術的進步提高了水腦症的診斷率，使腦脊髓液管理裝置對醫師更具吸引力。抗菌塗層導管等創新技術可望改善臨床療效，同時也將推高平均售價（ASP）。此外，全球人口老化和創傷性腦損傷發生率的上升也促使分流和引流產品在預測期內的患者群體不斷擴大。

另一方面，醫療預算緊張以及現有分流系統臨床療效已足夠，限制了企業引進高成本創新設備的意願，從而限制了市場成長。因此，產品創新步伐緩慢，與其他神經系統醫療設備領域相比，整體市場成長也較為溫和。

市場概覽

全球腦脊髓液（CSF）管理市場主要針對水腦症及其他需要控制性引流腦脊髓液的相關疾病的治療。腦脊髓液分流器和體外引流系統是兩大主要醫療設備類別，其中分流器作為長期植入式解決方案，佔據了大部分市場佔有率。自現代分流器問世以來，水腦症的基本治療方法並未發生顯著變化，市場也因此經歷了緩慢但穩定的成長，反映了其結構穩定性。

過去幾十年，腦脊髓液分流閥設計的進步推動了該市場的主要技術創新。壓力可調系統使醫生能夠使用手持器械非侵入性地調整分流設置，從而改善患者管理並減少不必要的再次手術。磁振造影相容的分流組件解決了需要持續進行神經影像檢查的患者面臨的一項重要臨床限制，其日益普及也促使醫生更傾向於選擇這一新一代產品。這些創新在不從根本改變治療框架的前提下，提高了腦脊髓液分流裝置的臨床應用價值。

抗菌塗層導管是短期內腦脊髓液分流市場最重要的創新產品。分流感染是水腦症治療中最嚴重且最常見的併發症之一，而旨在降低導管遠端感染風險的塗層可以顯著改善患者預後並減少再次手術的需求。抗菌系統在臨床上的日益普及預計將在預測期內推高平均售價 (ASP)，並擴大分流器領域的商機。

醫療機構的預算限制仍然是該市場長期存在的結構性問題。當現有分流系統在臨床上夠有效時，醫療機構往往不願意承擔創新替代方案所帶來的額外成本。這限制了製造商投資先進產品研發的獎勵，形成惡性循環，減緩了創新步伐和市場成長。歐盟等地區的政府政策舉措有可能產生連鎖反應，打破這種局面，但其短期影響仍不明朗。

市場促進因素

人口統計因素

與其他族群相比，水腦症在老年族群的發生率更高。隨著全球人口老化，預計在預測期內，腦積水的整體發生率將持續上升。隨著水腦症患者數量的增加，對分流器和外引流產品的需求也將擴大，從而帶動這兩個領域手術數量的成長。創傷性腦損傷（TBI）發生率的上升也促進了對外引流系統的需求，因為TBI患者在急性神經系統治療中通常需要臨時性腦脊髓液（CSF）引流。這些人口結構和創傷趨勢正在形成一個穩定且不斷擴大的患者群體，預計即使在創新步伐有限、價格漲幅受限的市場環境下，該群體仍將支撐手術數量的適度成長，直至2032年。

技術進步

新型分流技術的出現使腦脊髓液管理裝置對醫師更具吸引力。此外，顱內壓監測技術的進步提高了水腦症的診斷準確性，並擴大了符合治療條件的患者群體。抗菌導管有望成為腦脊髓液分流市場下一個重大創新。應用於導管遠端的塗層旨在降低感染風險和相關的再次手術負擔。這些系統在臨床實踐中的成功應用預計將推高平均售價 (ASP)，並推動市場價值的逐步成長。壓力調節閥技術和磁振造影相容組件的持續發展也促進了醫生對這些裝置的接受度，並增強了現有分流方案產品升級的合理性。

市場限制

分流術有效性和併發症發生率

人們對水腦症的認知進展緩慢，治療方法幾十年來基本上沒有改變。腦脊髓液分流器在正常運作的情況下雖然有效，但可能引發多種併發症，且往往需要再次手術。如果分流器阻塞、感染或移位，症狀可能會復發。這些併發症可能導致一系列後果，從頭痛、噁心和嘔吐到更嚴重的後果，例如癲癇發作和認知障礙。許多水腦症患者一生中至少需要一次再次手術，這增加了手術風險和患者負擔，但並未顯著提高醫療設備的銷售。此外，磁振造影相容性的限制也增加了植入磁性分流器組件患者的臨床複雜性，需要在常規神經系統監測期間採取特定的安全措施。

缺乏創新和預算限制

醫療機構預算有限，現有分流系統臨床效果良好時，往往不願意採用更昂貴、更具創新性的設備。自1960年代水腦症分流器的基本設計確立以來，除了引入可調式壓力閥外，該領域幾乎沒有發生任何變化。由於醫院和醫療機構管理者對成本較為敏感，採用新一代產品的可能性較低，這限制了製造商進行相關投資的商業性獎勵。這就形成了一個惡性循環：醫療機構和製造商都不願在最尖端科技投入資源，阻礙了產品開發和整體市場成長。歐盟層級支持醫療設備創新的項目等外部政策舉措，可望在預測期內打破這項循環。

目錄

調查方法

• 第一步：專案推出與團隊組建
• 步驟二：資料系統開發與二次調查實施
• 步驟三：準備面試設計問卷
• 第四步：進行初步調查
• 第五步：調查與分析：估計值基準估計
• 第六步：市場預測與分析
• 第七步：辨識策略機遇
• 步驟 8：最終確認和市場公告
• 步驟九：客戶回饋與市場監測

全球關稅的影響

腦脊髓液管理市場

• 執行摘要
  • 全球腦脊髓液管理市場概覽
  • 競爭分析
  • 涵蓋的治療
  • 目標市場
  • 目標區域
• 介紹
• 治療次數
  • 腦脊髓液分流手術總數
  • 慢性疲勞症候群手術總數
  • 分流植入
  • 分流器置換手術
• 市場概覽
  • 按細分市場
  • 按地區
• 市場分析與預測
  • 腦脊髓液管理市場
  • 腦脊髓液分流市場
  • 腦脊髓液引流系統市場
• 促進因素和抑制因素
  • 市場促進因素
  • 市場限制因素
• 競爭性市佔率分析

附錄

The global cerebrospinal fluid (CSF) management market was valued at approximately $327 million in 2025. The market is expected to grow at a compound annual growth rate (CAGR) of 2.8%, reaching approximately $397 million by 2032.

• This report covers two primary device segments: CSF shunts and CSF external drainage systems. The report quantifies unit sales, procedure numbers, average selling prices (ASPs), market values, growth rates, and company shares, with historical data back to 2022 and forecasts through 2032.

Emerging shunt technologies and advancements in intracranial pressure (ICP) monitoring are improving hydrocephalus diagnosis rates and making CSF management devices more attractive to physicians. Innovations such as antimicrobial-coated catheters are expected to enhance clinical outcomes while supporting higher ASPs. An aging global population and rising rates of traumatic brain injury are also providing a growing patient base for both shunt and drainage products over the forecast period.

The market is constrained by tight healthcare budgets and limited willingness to adopt higher-cost innovative devices when existing shunt systems remain clinically sufficient. This dynamic has historically slowed product innovation and moderated overall market growth relative to other neurological device segments.

Market Overview

The global CSF management market addresses the treatment of hydrocephalus and related conditions requiring controlled drainage of cerebrospinal fluid. CSF shunts and external drainage systems are the two primary device categories, with shunts accounting for the majority of market value as long-term implantable solutions. The fundamental treatment approach for hydrocephalus has seen limited change since the introduction of the modern shunt, and the market reflects this structural stability through modest but consistent growth.

Advancements in shunt valve design have driven the primary technology evolution in this market over recent decades. Adjustable pressure systems allow physicians to modify shunt settings non-invasively using hand-held tools, improving patient management and reducing unnecessary revision procedures. MRI-compatible shunt components address a key clinical constraint for patients requiring ongoing neurological imaging, and their increasing availability is supporting physician preference for newer product generations. These innovations are making CSF devices more clinically attractive without fundamentally changing the treatment framework.

Antimicrobial-coated catheters represent the most significant near-term product innovation in the CSF shunt market. Shunt infections are among the most serious and common complications in hydrocephalus management, and coatings designed to reduce infection risk at the distal catheter ends could meaningfully improve patient outcomes and reduce the need for revision surgery. Broader clinical adoption of antimicrobial systems is expected to support ASP growth and expand the revenue opportunity within the shunt segment over the forecast period.

Healthcare provider budget constraints remain a persistent structural feature of this market. When existing shunt systems are clinically sufficient, facilities are reluctant to absorb the cost premium of innovative alternatives. This limits manufacturer incentives to invest in advanced product development and creates a cycle that moderates both innovation pace and market growth. Government policy initiatives in regions such as the European Union have the potential to introduce spillover effects that disrupt this dynamic, though their near-term impact remains uncertain.

Market Drivers

Demographic Factors

Hydrocephalus affects older populations at a higher rate than other demographics, and the aging global population is expected to increase the overall incidence of the condition over the forecast period. As more patients develop hydrocephalus, demand for both shunts and external drainage products will grow, supporting procedural volume across both device segments. Rising rates of traumatic brain injury are also contributing to demand for external drainage systems, as TBI patients frequently require temporary CSF drainage as part of acute neurological care. These demographic and injury trends provide a stable and expanding patient base that supports moderate procedural growth through 2032, even within a market characterized by limited innovation pace and constrained pricing growth.

Advancing Technology

Emerging shunt technologies are making CSF management devices a more attractive option for physicians, while advancements in intracranial pressure monitoring are improving hydrocephalus diagnosis rates and expanding the treated patient population. Antimicrobial catheters represent the next significant innovation push in the CSF shunt market, with coatings applied to the distal catheter ends designed to reduce infection risk and the associated burden of revision surgery. Successful clinical adoption of these systems is expected to support higher ASPs and generate incremental market value growth. Continued development of adjustable pressure valve technology and MRI-compatible components also supports physician adoption and strengthens the case for product upgrades in established shunt programs.

Market Limiters

Shunt Efficacy and Complication Rates

The understanding of hydrocephalus as a disease has advanced slowly, and treatment approaches have remained largely consistent for decades. While CSF shunts are effective when functioning correctly, they are subject to a range of complications that frequently require revision surgery. Shunts can become blocked, infected, or disconnected, causing symptoms to re-emerge. Consequences range from headaches, nausea, and vomiting to more serious outcomes including seizures and cognitive dysfunction. Most hydrocephalus patients will require at least one revision procedure during their lifetime, adding surgical risk and patient burden without generating meaningful incremental device revenue. MRI compatibility constraints also add clinical complexity for patients with magnetic shunt components, requiring specific safety protocols during routine neurological monitoring.

Lack of Innovation and Budget Constraints

Healthcare centers operate under limited budgets and are hesitant to adopt more expensive innovative devices when existing shunt systems provide adequate clinical performance. Since the fundamental design of the hydrocephalus shunt was established in the 1960s, the category has changed relatively little beyond the introduction of the adjustable pressure valve. Manufacturers face limited commercial incentives to invest in next-generation products when adoption is unlikely due to cost sensitivity among hospital and facility administrators. This creates a negative feedback dynamic where neither providers nor manufacturers are willing to commit resources to premium technology, suppressing both product development and overall market growth. External policy initiatives, such as EU-level programs supporting medical device innovation, have the potential to disrupt this cycle over the forecast period.

Market Coverage and Data Scope

• Quantitative coverage: Procedure numbers, market size, market shares, market forecasts, growth rates, units sold, and average selling prices.
• Qualitative coverage: Growth trends, market limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles and product portfolios, and technology trends shaping demand.
• Time frame: Base year 2025, forecasts 2026 to 2032, historical data 2022 to 2024.
• Data sources: Primary interviews with neurological device industry leaders and neurosurgeons, regulatory data, hospital procurement data, import and export data, and the iData Research internal database.
• Care settings: Hospitals, neurosurgical specialty centers, and ambulatory care facilities.

Markets Covered and Segmentation

• The CSF management market is analyzed across two primary device segments, each assessed by unit volume, ASP, and market value with historical and forecast data:
• CSF Shunt
• CSF External Drainage System

Competitive Analysis

Medtronic led the cerebrospinal fluid management market in 2025, holding strong positions in both the shunt and external drainage segments. The company's PS Medical Strata valves offer non-invasive pressure adjustment through hand-held physician tools, providing over-drainage protection and compatibility with both ventricular and distal catheter configurations. MRI compatibility is a key product feature, addressing one of the primary clinical management challenges for shunt patients who require ongoing neurological imaging throughout their care.

Integra LifeSciences held the second position in the global CSF management market in 2025. The company's portfolio includes the CODMAN shunt systems, a well-established product line within the hydrocephalus management segment, alongside the BACTISEAL and HAKIM BACTISEAL systems. The BACTISEAL product line incorporates antimicrobial technology, positioning Integra within the growing segment of infection-reducing CSF devices and aligning the company with the broader clinical push toward catheter systems designed to reduce shunt-related infection rates.

B. Braun held the third position in the global CSF management market in 2025. The company competes through its MIETHKE proGAV 2.0, proGAV, and MIETHKE GAV adjustable gravitational shunt valves. These products address the clinical need for pressure management that accounts for changes in patient posture, a specific challenge in ambulatory shunt patients where gravitational pressure variation can affect CSF drainage rates. B. Braun's focus on gravitational valve technology provides a differentiated position within the broader adjustable shunt segment.

Technology and Practice Trends

• Adjustable pressure shunt valves: Non-invasive adjustable valves are increasingly standard in new shunt placements, allowing pressure settings to be modified without additional surgery and reducing unnecessary revision procedures.
• MRI-compatible shunt components: Growing demand for MRI-compatible systems is reducing the imaging constraints faced by shunt patients and supporting physician preference for newer product generations that do not require special safety protocols.
• Antimicrobial catheter coatings: Antimicrobial-coated catheters represent the primary innovation focus in the CSF shunt market, with the potential to reduce infection rates, lower revision burdens, and support ASP growth for manufacturers.
• Intracranial pressure monitoring advances: Improvements in ICP monitoring technology are improving hydrocephalus diagnosis rates, expanding the identified patient population and supporting procedural volume growth in both device segments.
• External drainage system growth: Rising rates of traumatic brain injury and acute neurological conditions are increasing demand for temporary CSF drainage systems in hospital and neurosurgical settings.
• Gravitational valve design: Shunt valves that account for positional pressure changes in ambulatory patients represent a specialized innovation area with clinical relevance for active patients managing long-term hydrocephalus.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

• Where are the largest and fastest-growing opportunities within the global CSF management market through 2032?
• How are advancements in adjustable pressure valves, MRI-compatible components, and antimicrobial catheters influencing product adoption and ASP trends?
• What is driving growth in the external drainage system segment, and how does traumatic brain injury incidence affect procedural volume forecasts?
• How do budget constraints and the lack of product innovation create a self-reinforcing cycle that limits market growth, and what could disrupt it?
• Which companies lead each device segment and what are their current product platforms and competitive strategies?
• What are the clinical implications of shunt complication rates and revision burdens for long-term device market dynamics?
• How do MRI compatibility requirements shape physician preferences and purchasing decisions for shunt valve systems?
• What are the key risks to growth, including innovation inertia, reimbursement constraints, and the slow pace of change in hydrocephalus treatment protocols?

The Global Cerebrospinal Fluid Management Market Report from iData Research answers these questions with procedure-aware models, company share analysis, and pricing detail. Use it to quantify demand, benchmark competitors, prioritize product development investments, and plan for growth across all major global regions.

TABLE OF CONTENT

Research Methodology

• Step 1: Project Initiation & Team Selection
• Step 2: Prepare Data Systems And Perform Secondary Research
• Step 3: Preparation For Interviews & Questionnaire Design
• Step 4: Performing Primary Research
• Step 5: Research Analysis: Establishing Baseline Estimates
• Step 6: Market Forecast And Analysis
• Step 7: Identify Strategic Opportunities
• Step 8: Final Review And Market Release
• Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

Cerebrospinal Fluid Management Market

• 4.1 Executive Summary
  • 4.1.1 Global Cerebrospinal Fluid Management Market Overview
  • 4.1.2 Competitive Analysis
  • 4.1.3 Procedures Included
  • 4.1.4 Markets Included
  • 4.1.5 Regions Included
• 4.2 Introduction
• 4.3 Procedure Numbers
  • 4.3.1 Total Cerebrospinal Fluid Shunting Procedures
  • 4.3.2 Total CFS Procedures
  • 4.3.3 Shunt Implantation Procedures
  • 4.3.4 Shunt Replacement Procedures
• 4.4 Market Overview
  • 4.4.1 By Segment
  • 4.4.2 By Region
• 4.5 Market Analysis And Forecast
  • 4.5.1 Total Cerebrospinal Fluid Management Market
  • 4.5.2 Cerebrospinal Fluid Shunt Market
    • 4.5.2.1 Adjustable Pressure Market
    • 4.5.2.2 Fixed Pressure Market
  • 4.5.3 Cerebrospinal Fluid Drainage System Market
    • 4.5.3.1 Ventricular Market
    • 4.5.3.2 Lumbar Market
    • 4.5.3.3 Ventricular/Lumbar Market
• 4.6 Drivers And Limiters
  • 4.6.1 Market Drivers
  • 4.6.2 Market Limiters
• 4.7 Competitive Market Share Analysis

Appendix

LIST OF CHARTS

• Chart 4-1: Cerebrospinal Fluid Management Market, Global, 2025 & 2032
• Chart 4-2: Cerebrospinal Fluid Management Procedures, Global, 2025
• Chart 4-3: CFS Procedures by Region, Global, 2022 - 2032
• Chart 4-4: Cerebrospinal Fluid Management Market by Segment, Global, 2022 - 2032
• Chart 4-5: Cerebrospinal Fluid Management Market by Region, Global, 2022 - 2032
• Chart 4-6: Leading Competitors, Cerebrospinal Fluid Management Market, Global, 2025

LIST OF FIGURES

• Figure 4-1: Cerebrospinal Fluid Management Procedures Covered
• Figure 4-2: Cerebrospinal Fluid Management Markets Covered
• Figure 4-3: Cerebrospinal Fluid Management Regions Covered, Global (1 of 2)
• Figure 4-4: Cerebrospinal Fluid Management Regions Covered, Global (2 of 2)
• Figure 4-5: CFS Procedures by Segment, Global, 2022 - 2032
• Figure 4-6: CFS Procedures by Region, Global, 2022 - 2032
• Figure 4-7: CFS Procedures by Country, North America, 2022 - 2032
• Figure 4-8: CFS Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 4-9: CFS Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 4-10: CFS Procedures by Country, Western Europe, 2022 - 2032
• Figure 4-11: CFS Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 4-12: CFS Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 4-13: CFS Procedures by Country, Middle East, 2022 - 2032
• Figure 4-14: CFS Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 4-15: CFS Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 4-16: CFS Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 4-17: CFS Procedures by Country, Africa, 2022 - 2032
• Figure 4-18: Shunt Implanation Procedures by Region, Global, 2022 - 2032
• Figure 4-19: Shunt Implantation Procedures by Country, North America, 2022 - 2032
• Figure 4-20: Shunt Implantation Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 4-21: Shunt Implantation Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 4-22: Shunt Implantation Procedures by Country, Western Europe, 2022 - 2032
• Figure 4-23: Shunt Implantation Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 4-24: Shunt Implantation Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 4-25: Shunt Implantation Procedures by Country, Middle East, 2022 - 2032
• Figure 4-26: Shunt Implantation Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 4-27: Shunt Implantation Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 4-28: Shunt Implantation Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 4-29: Shunt Implantation Procedures by Country, Africa, 2022 - 2032
• Figure 4-30: Shunt Replacement Procedures by Region, Global, 2022 - 2032
• Figure 4-31: Shunt Replacement Procedures by Country, North America, 2022 - 2032
• Figure 4-32: Shunt Replacement Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 4-33: Shunt Replacement Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 4-34: Shunt Replacement Procedures by Country, Western Europe, 2022 - 2032
• Figure 4-35: Shunt Replacement Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 4-36: Shunt Replacement Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 4-37: Shunt Replacement Procedures by Country, Middle East, 2022 - 2032
• Figure 4-38: Shunt Replacement Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 4-39: Shunt Replacement Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 4-40: Shunt Replacement Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 4-41: Shunt Replacement Procedures by Country, Africa, 2022 - 2032
• Figure 4-42: Cerebrospinal Fluid Management Market by Segment, Global, 2022 - 2032 (US$M)
• Figure 4-43: Cerebrospinal Fluid Management Market by Region, Global, 2022 - 2032 (US$M)
• Figure 4-44: Cerebrospinal Fluid Management Market, Global, 2022 - 2032
• Figure 4-45: Units Sold by Region, Cerebrospinal Fluid Management Market, Global, 2022 - 2032
• Figure 4-46: Average Selling Price by Region, Cerebrospinal Fluid Management Market, Global, 2022 - 2032 (US$)
• Figure 4-47: Market Value by Region, Cerebrospinal Fluid Management Market, Global, 2022 - 2032 (US$M)
• Figure 4-48: Cerebrospinal Fluid Shunt Market by Segment, Global, 2022 - 2032 (US$M)
• Figure 4-49: Total Cerebrospinal Fluid Shunt Market, Global, 2022 - 2032
• Figure 4-50: Units Sold by Region, Cerebrospinal Fluid Shunt Market, Global, 2022 - 2032
• Figure 4-51: Average Selling Price by Region, Cerebrospinal Fluid Shunt Market, Global, 2022 - 2032 (US$)
• Figure 4-52: Market Value by Region, Cerebrospinal Fluid Shunt Market, Global, 2022 - 2032 (US$M)
• Figure 4-53: Adjustable Pressure Surgical Graft Market, Global, 2022 - 2032
• Figure 4-54: Units Sold by Region, Adjustable Pressure Surgical Graft Market, Global, 2022 - 2032
• Figure 4-55: Average Selling Price by Region, Adjustable Pressure Surgical Graft Market, Global, 2022 - 2032 (US$)
• Figure 4-56: Market Value by Region, Adjustable Pressure Surgical Graft Market, Global, 2022 - 2032 (US$M)
• Figure 4-57: Fixed Pressure Surgical Graft Market, Global, 2022 - 2032
• Figure 4-58: Units Sold by Region, Fixed Pressure Surgical Graft Market, Global, 2022 - 2032
• Figure 4-59: Average Selling Price by Region, Fixed Pressure Surgical Graft Market, Global, 2022 - 2032 (US$)
• Figure 4-60: Market Value by Region, Fixed Pressure Surgical Graft Market, Global, 2022 - 2032 (US$M)
• Figure 4-61: Cerebrospinal Fluid Drainage System Graft Market by Segment, Global, 2022 - 2032 (US$M)
• Figure 4-62: Total Cerebrospinal Fluid Drainage System Graft Market, Global, 2022 - 2032
• Figure 4-63: Units Sold by Region, Cerebrospinal Fluid Drainage System Graft Market, Global, 2022 - 2032
• Figure 4-64: Average Selling Price by Region, Cerebrospinal Fluid Drainage System Graft Market, Global, 2022 - 2032 (US$)
• Figure 4-65: Market Value by Region, Cerebrospinal Fluid Drainage System Graft Market, Global, 2022 - 2032 (US$M)
• Figure 4-66: Ventricular Market, Global, 2022 - 2032
• Figure 4-67: Units Sold by Region, Ventricular Market, Global, 2022 - 2032
• Figure 4-68: Average Selling Price by Region, Ventricular Market, Global, 2022 - 2032 (US$)
• Figure 4-69: Market Value by Region, Ventricular Market, Global, 2022 - 2032 (US$M)
• Figure 4-70: Lumbar Market, Global, 2022 - 2032
• Figure 4-71: Units Sold by Region, Lumbar Market, Global, 2022 - 2032
• Figure 4-72: Average Selling Price by Region, Lumbar Market, Global, 2022 - 2032 (US$)
• Figure 4-73: Market Value by Region, Lumbar Market, Global, 2022 - 2032 (US$M)
• Figure 4-74: Ventricular/Lumbar Market, Global, 2022 - 2032
• Figure 4-75: Units Sold by Region, Ventricular/Lumbar Market, Global, 2022 - 2032
• Figure 4-76: Average Selling Price by Region, Ventricular/Lumbar Market, Global, 2022 - 2032 (US$)
• Figure 4-77: Market Value by Region, Ventricular/Lumbar Market, Global, 2022 - 2032 (US$M)
• Figure 4-78: Leading Competitors, Cerebrospinal Fluid Management Market, Global, 2025